For treatment of pancreatic cancer, a combination of CD40 agonist with radiotherapy is currently under investigation in one clinical study (NCT02311361) and combination of CD40 agonist with chemotherapy based on gemcitabine, nab-paclitaxel and nivolumab is used in a clinical phase I/II trial (NCT 03214250). This evidence concerns the gene CD40 and familial pancreatic carcinoma.